Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
Crossref DOI link: https://doi.org/10.1007/s40273-019-00857-7
Published Online: 2019-11-12
Published Print: 2020-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wehler, Elizabeth http://orcid.org/0000-0001-5059-882X
Boytsov, Natalie
Nicolay, Claudia
Herrera-Restrepo, Oscar
Kowal, Stacey
Text and Data Mining valid from 2019-11-12
Version of Record valid from 2019-11-12
Article History
First Online: 12 November 2019